RU94042922A - Новые соединения, способы их получения, фармацевтическая композиция - Google Patents

Новые соединения, способы их получения, фармацевтическая композиция

Info

Publication number
RU94042922A
RU94042922A RU94042922/04A RU94042922A RU94042922A RU 94042922 A RU94042922 A RU 94042922A RU 94042922/04 A RU94042922/04 A RU 94042922/04A RU 94042922 A RU94042922 A RU 94042922A RU 94042922 A RU94042922 A RU 94042922A
Authority
RU
Russia
Prior art keywords
production
pharmaceutical composition
novel compounds
mammals
pharmaceutical compositions
Prior art date
Application number
RU94042922/04A
Other languages
English (en)
Other versions
RU2147304C1 (ru
Inventor
Фрэнсис Хит Вилльям (младший)
Us]
Роберт Джиросек Майкл
Хэмптон МакДональд Ш Джон
Джон Рито Кристофер
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94042922A publication Critical patent/RU94042922A/ru
Application granted granted Critical
Publication of RU2147304C1 publication Critical patent/RU2147304C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение относится к новым бис-индолмалеимидным макроциклическим производным формулы. Кроме того, изобретение относится к получению указанных соединений, к их фармацевтическим композициям и способам их использования для ингибирования протеинкиназы С у млекопитающих.

Claims (1)

  1. Изобретение относится к новым бис-индолмалеимидным макроциклическим производным формулы
    Figure 00000001
    . Кроме того, изобретение относится к получению указанных соединений, к их фармацевтическим композициям и способам их использования для ингибирования протеинкиназы С у млекопитающих.
RU94042922A 1993-12-07 1994-12-02 Бис-индолмалеимидные макроциклические производные, способ их получения (варианты) и фармацевтическая композиция RU2147304C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US08/163.060 1993-12-07
US08/163,060 1993-12-07
US31697394A 1994-10-03 1994-10-03
US08/316.973 1994-10-03
US08/316,973 1994-10-03

Publications (2)

Publication Number Publication Date
RU94042922A true RU94042922A (ru) 1996-12-27
RU2147304C1 RU2147304C1 (ru) 2000-04-10

Family

ID=26859318

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94042922A RU2147304C1 (ru) 1993-12-07 1994-12-02 Бис-индолмалеимидные макроциклические производные, способ их получения (варианты) и фармацевтическая композиция

Country Status (31)

Country Link
US (1) US5698578A (ru)
EP (1) EP0657458B1 (ru)
JP (2) JP3581731B2 (ru)
KR (1) KR100340159B1 (ru)
CN (2) CN1050844C (ru)
AT (1) ATE204579T1 (ru)
AU (1) AU687909B2 (ru)
BR (1) BR9404831A (ru)
CA (1) CA2137203C (ru)
CO (1) CO4340622A1 (ru)
CY (1) CY2413B1 (ru)
CZ (1) CZ291950B6 (ru)
DE (1) DE69428025T2 (ru)
DK (1) DK0657458T3 (ru)
ES (1) ES2162843T3 (ru)
FI (3) FI108138B (ru)
GR (1) GR3037087T3 (ru)
HK (1) HK1013827A1 (ru)
HU (1) HU219709B (ru)
IL (1) IL111850A (ru)
MY (1) MY125587A (ru)
NO (1) NO308798B1 (ru)
NZ (1) NZ270048A (ru)
PE (1) PE49195A1 (ru)
PL (1) PL182124B1 (ru)
PT (1) PT657458E (ru)
RU (1) RU2147304C1 (ru)
SG (1) SG63570A1 (ru)
TW (1) TW425397B (ru)
UA (1) UA44690C2 (ru)
YU (1) YU49200B (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
KR100342142B1 (ko) * 1995-11-20 2002-08-22 일라이 릴리 앤드 캄파니 신규한중간체및n,n'-가교된비스인돌릴말레이미드를제조하기위한그의용도
EA000967B1 (ru) * 1995-11-20 2000-08-28 Эли Лилли Энд Компани Ингибитор протеинкиназы c
EP0888339A4 (en) * 1996-03-20 2001-02-28 Lilly Co Eli SYNTHESIS OF INDOLYLMALEINIMIDES
CN1233177A (zh) 1996-05-01 1999-10-27 伊莱利利公司 Vegf相关疾病的治疗
WO1997041127A1 (en) * 1996-05-01 1997-11-06 Eli Lilly And Company Halo-substituted protein kinase c inhibitors
UA54427C2 (ru) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Способ лечения заболеваний глаз, связанных с фактором роста эндотелия сосудов
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
IL128494A0 (en) * 1996-08-30 2000-01-31 Lilly Co Eli Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
WO1998008510A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
EP1061062B1 (en) 1998-01-30 2009-02-18 Daiso Co., Ltd. Process for producing butanetriol derivatives
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
ATE251624T1 (de) * 1998-03-13 2003-10-15 Univ British Columbia Granulatimide-derivate zur behandlung von krebs
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
RU2275373C2 (ru) * 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
EP1790353A1 (en) * 2001-12-29 2007-05-30 Novo Nordisk A/S Combined use of a GLP-1 compound and a modulator of diabetic late complications
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
EP2210612B1 (en) 2003-06-18 2016-10-05 Ocera Therapeutics, Inc. Macrocyclic antagonists of the motilin receptor
EP2305265A1 (en) 2003-08-08 2011-04-06 Novartis AG Combinations comprising staurosporines
CA2601278C (en) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
EP1998776A4 (en) * 2006-03-10 2009-07-08 Janssen Pharmaceutica Nv MACRO-HETEROCYL COMPOUNDS CONTAINING PYRIDINE AS KINASE INHIBITORS
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
KR20140107685A (ko) 2010-03-30 2014-09-04 노파르티스 아게 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
UA115250C2 (uk) 2012-11-29 2017-10-10 Новартіс Аг Фармацевтичні комбінації
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
CN108026109B (zh) * 2015-07-21 2021-03-02 特普医药公司 手性二芳基大环及其用途
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
SG11202000356VA (en) 2017-07-28 2020-02-27 Turning Point Therapeutics Inc Macrocyclic compounds and uses thereof
PT3728271T (pt) 2017-12-19 2022-10-06 Turning Point Therapeutics Inc Compostos macrocíclicos para tratar doenças
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof
WO2024159211A1 (en) * 2023-01-27 2024-08-02 Mellicell, Inc. Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
JPH06503837A (ja) * 1991-04-11 1994-04-28 シェリング・コーポレーション 抗腫瘍および抗乾癬薬
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
HUT71130A (en) 1995-11-28
JP3581731B2 (ja) 2004-10-27
CA2137203C (en) 2006-11-28
NZ270048A (en) 1996-11-26
FI108138B (fi) 2001-11-30
DE69428025T2 (de) 2002-05-29
CZ291950B6 (cs) 2003-06-18
EP0657458A1 (en) 1995-06-14
IL111850A0 (en) 1995-03-15
US5698578A (en) 1997-12-16
CN1055089C (zh) 2000-08-02
PT657458E (pt) 2002-02-28
KR100340159B1 (ko) 2002-11-23
CZ301894A3 (en) 1995-06-14
GR3037087T3 (en) 2002-01-31
MY125587A (en) 2006-08-30
AU687909B2 (en) 1998-03-05
AU7918894A (en) 1995-06-15
CO4340622A1 (es) 1996-07-30
FI945706A0 (fi) 1994-12-02
UA44690C2 (uk) 2002-03-15
FI945706A (fi) 1995-06-08
CN1050844C (zh) 2000-03-29
CN1111247A (zh) 1995-11-08
BR9404831A (pt) 1995-08-08
KR950018010A (ko) 1995-07-22
IL111850A (en) 2002-11-10
FI20000516A (fi) 2000-03-07
YU70494A (sh) 1997-03-07
FI20011109A (fi) 2001-05-28
HU219709B (hu) 2001-06-28
DK0657458T3 (da) 2001-10-29
ATE204579T1 (de) 2001-09-15
NO944643L (no) 1995-06-08
SG63570A1 (en) 1999-03-30
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
YU49200B (sh) 2004-09-03
JP2004269543A (ja) 2004-09-30
DE69428025D1 (de) 2001-09-27
HK1013827A1 (en) 1999-09-10
ES2162843T3 (es) 2002-01-16
CN1220266A (zh) 1999-06-23
HU9403468D0 (en) 1995-02-28
RU2147304C1 (ru) 2000-04-10
NO308798B1 (no) 2000-10-30
CA2137203A1 (en) 1995-06-08
TW425397B (en) 2001-03-11
EP0657458B1 (en) 2001-08-22
JPH07215977A (ja) 1995-08-15
PL182124B1 (pl) 2001-11-30
NO944643D0 (no) 1994-12-02
CY2413B1 (en) 2004-11-12

Similar Documents

Publication Publication Date Title
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
YU60996A (sh) Inhibitor protein kinaze c, njegove faramceutske formulacije i postupak za dobijanje
BG103417A (en) Condensed pyrimidine bicyclic derivatives
CA2216535A1 (en) Protein kinase c inhibitors
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
YU40997A (sh) Novi oksadiazoli, postupci za njihovo pripremanje
EA199901014A1 (ru) C-4"-замещенные макролидные производные
ATE316083T1 (de) Adamantanderivate
AU4627097A (en) Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
ATE204278T1 (de) Serotoninergische ergolin derivate
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
NO20010624D0 (no) N-substituerte azacykloheptanderivater, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20121203